Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetes
- Diabetes Type 2
- FATTY LIVER
- Fatty Liver, Nonalcoholic
- NAFLD
- NASH
- NASH - Nonalcoholic Steatohepatitis
- Type 2 Diabetes
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Subjects assigned to receive empagliflozin will be dosed at 10 mg per day for the duration of the study. Approximately 30 subjects will be enrolled per treatment arm.
Subjects assigned to receive empagliflozin will be dosed at 10 mg per day for the duration of the study. Approximately 30 subjects will be enrolled per treatment arm.
Tracking Information
- NCT #
- NCT04702490
- Collaborators
- Not Provided
- Investigators
- Study Chair: Hubert C Chen, MD Metacrine, Inc.
Get Well Soon